- 5
- 0
- 约1.74万字
- 约 18页
- 2017-05-05 发布于浙江
- 举报
Minimally invasive endovascular treatment of descending aortic diseases
PAGE \* MERGEFORMAT 18
Minimally invasive endovascular treatment of descending aortic diseases
Author: Shi Xin Bao Le-Bo Shao Feng Sun
【Abstract】 Objective To review the minimally invasive endovascular treatment of descending aortic diseases of experience and near mid-term results. Methods Summary hospital from April 2004 to November 2008 OK endovascular clinical data of 27 patients, including acute Stanford “B”-type dissection in 16 cases, descending aorta pseudoaneurysm l1 cases (including the five exceptions Traumatic pseudoaneurysm in the descending aorta, descending aorta in 5 cases of penetrating ulcer and 1 case of infected descending aortic pseudoaneurysm). Results 26 patients surgery was successful, a traumatic descending aortic rupture in patients with completely, because the guide wire into the ascending aorta can not be true cavity, minimally invasive surgery fails, switch to line descending thoracic aortic replacement surgery. Successful endovascular exclusion of 26 cases, all at once after descending aorta Break away, real-cavity to expand. Early postoperative death (1 case died 2 weeks after the operation bleeding gastric ulcer); internal leakage occurred in 2 cases of type Ⅰ, Ⅱ type 1 cases of internal leakage; no postoperative paraplegia, infection, complications such as distal embolization of vascular injuries. Successful endovascular exclusion of 26 patients discharged from hospital in 25 cases. Patients were followed up 1 month to 4 years, stent-graft patency, no shift, real cavity expanding false lumen to narrow or disappear. CT reviewed after 3 months, 2 cases of type Ⅰ internal leakage in 1 case disappeared completely internal leakage, and 1 to reduce internal leakage (continued follow-up), 1 patients with type Ⅱ no change in leakage. Conclusion Endovascular graft exclusion for Stanford “B”-type dissecting aneurysm and descending thoracic aortic pseudoaneurysm trauma, safe and reliable, near mid-term curative effect.
您可能关注的文档
- Mifepristone and misoprostol and one-time termination of cervical dilation rod 12 to understand the efficacy of 16 weeks of pregnancy.doc
- Mifepristone and misoprostol for surgery in postmenopausal women taking control of 86 Cases.doc
- Mifepristone and misoprostol for medical abortion in different ways compatible clinical comparative study.doc
- Mifepristone and misoprostol for missed abortion Efficacy of 490 Cases.doc
- Mifepristone and misoprostol for termination of pregnancy efficacy of medium-term.doc
- Mifepristone and misoprostol for termination from 12 to 20 weeks Pregnancy.doc
- Mifepristone and misoprostol and mid-pregnancy termination rivanol Comparison.doc
- Mifepristone and misoprostol for termination of pregnancy from 12 to 16 weeks clinical observation.doc
- Mifepristone and misoprostol for termination of pregnancy from 5 to 18 weeks compared.doc
- Mifepristone and misoprostol in early pregnancy induction of labor in the application of.doc
- 中国国家标准 GB/T 6675.9-2025玩具安全 第9部分:化学及类似活动的实验玩具.pdf
- 《GB/T 6675.9-2025玩具安全 第9部分:化学及类似活动的实验玩具》.pdf
- GB/T 46975-2025婴童用品 便携式婴儿睡篮技术要求.pdf
- 中国国家标准 GB/T 46975-2025婴童用品 便携式婴儿睡篮技术要求.pdf
- 《GB/T 46975-2025婴童用品 便携式婴儿睡篮技术要求》.pdf
- 《GB/T 6675.14-2025玩具安全 第14部分:指画颜料要求和测试方法》.pdf
- GB/T 6675.14-2025玩具安全 第14部分:指画颜料要求和测试方法.pdf
- 中国国家标准 GB/T 6675.14-2025玩具安全 第14部分:指画颜料要求和测试方法.pdf
- 中国国家标准 GB/T 33772.3-2025质量评定体系 第3部分:印制板及层压板最终产品检验及过程监督用抽样方案的选择和使用.pdf
- 《GB/T 33772.3-2025质量评定体系 第3部分:印制板及层压板最终产品检验及过程监督用抽样方案的选择和使用》.pdf
原创力文档

文档评论(0)